Third, given that ARRB1 deficiency simultaneously enhances T cell function and reduces MDSC populations, ARRB1 targeting could improve CAR-T cell therapy outcomes by creating a more favorable tumor microenvironment. The gene discussed is ARRB1; the disease is neoplasm.